Today, study startup functions and job roles are more commonplace at sponsor and CRO organizations, but despite this, clinical operations teams are drowning in data but starving for information at a time of intense pressure to speed up clinical trials and restrain costs.

TORONTO (PRWEB)
November 09, 2021

Until recently, the study startup portion of clinical trials has not benefited from innovation, essentially remaining manual or heavily rooted in Excel spreadsheets, causing this complex process to seriously underperform. The 10 steps to clinical study startup eBook, based on the directives in ICH E6(R1), helped define the site-specific activities at the outset of a clinical trial and to this day remains a very popular download.

Today, study startup functions and job roles are more commonplace at sponsor and CRO organizations, but despite this, clinical operations teams are drowning in data but starving for information at a time of intense pressure to speed up clinical trials and restrain costs.

The average cost of drug R&D is now estimated to be $2.9B by Tufts CSDD — this is unsustainable. Globalization (multi-country studies), the changing regulatory landscape (ICH E6(R2)/(R3), EU 536/2014, etc.), matrix organizational changes and non-traditional trial designs (e.g., decentralized clinical trials) have forced the industry to rethink their approach to study startup. These traditional steps need to be expanded upon, collapsed and fit for purpose. But, how?

Register for this live webinar on Tuesday, November 30, 2021 at 10am EST (3pm GMT/UK) to learn about a modern approach to study startup that addresses today’s drug development challenges.

The webinar will feature the following expert speakers:

• Gareth Milborrow, SVP of Feasibility, Site ID & Start-Up, ICON; ACRO member company;
• Lorena Gomez, Senior Director, Global Study Start Up, PRO Management, and Digital Implementation, AbbVie;
• Andrea Ochoa, VP of Global Study Start Up, Premier Research; CRO Forum member company;
• Kirill S. Soldatov, Director of Process Improvement, PSI CRO;
• Tina Karunaratne, Head of Global Clinical Operations, Orum Therapeutics;
• Jennifer Peterson, Executive Director, SSU & Regulatory, Syneos Health; ACRO member company; and
• Elvin Thalund, Director, Industry Strategy, Oracle Health Sciences, ACRO member company

For more information, or to register for this event, visit Moving Beyond 10 Steps to Clinical Study Startup.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Randomization and decentralized trials are well-suited to work together to provide the required information to the study and site personnel, especially when working with a remote team.

TORONTO (PRWEB)
November 09, 2021

Today’s clinical studies are more complex and involve more critical systems than ever before. They require close integration to minimize human error and maximize efficiency.

In this webinar, join partners endpoint and THREAD to explore the tightly integrated workflow for decentralized and hybrid studies.

For studies involving randomization, interactive response technology (IRT) is a critical component ensuring participants receive the correct study drug to authenticate the study hypothesis. Randomization and decentralized trials are well-suited to work together to provide the required information to the study and site personnel, especially when working with a remote team.

This webinar will focus on:

• 
      Randomizing with minimal site interaction
•     Minimizing duplication of data
•     Managing the re-screen process
•     Managing the re-consent process
•     Managing dispensation

Join Debbie Streahorn, Senior Program Manager, endpoint Clinical; and Jennifer Price, Executive Director, Data & Analytics, THREAD Research, in a live webinar on Tuesday, November 16, 2021 at 1pm EST to learn how IRT can be integrated with electronic data capture (EDC) systems to support decentralized and hybrid trials.

For more information, or to register for this event, visit Strengthen the Ties That Bind: Seamless IRT and EDC Integration.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Renegade’s SWEAT-X Free and Clear Laundry Detergent

“I am thrilled that through Renegade, the allergy aware consumer can now select a detergent that has passed our rigorous ASL standards, and is CERTIFIED asthma & allergy friendly®,” said Dr. John McKeon

WASHINGTON (PRWEB)
November 09, 2021

The Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL) has announced that Renegade’s SWEAT-X Free and Clear is the first laundry detergent to earn the asthma & allergy friendly® certification.

When used regularly to wash bedding and clothing, CERTIFIED asthma & allergy friendly® laundry detergent can help people reduce asthma and allergy triggers, which contributes to a healthier home environment.

The asthma & allergy friendly® Certification Program, an independent program established in the United States by AAFA and ASL, helps consumers identify products for the home that are more suitable for people with asthma and allergies. Products undergo physical and chemical testing to ensure they reduce allergen exposure and limit pollutants in the air. The certification mark is awarded only to those products that meet the criteria.

The Laundry Detergent Certification Standard tests fabric samples in an environmentally controlled chamber to simulate real world conditions, using cat allergens and dust mite allergens which are added to fabric for an incubation period. The samples are then washed in the laundry detergent, and upon completion of the wash, the fabric must show a reduction in allergen levels of 95% or greater.

Renegade’s SWEAT-X Free and Clear Laundry Detergent has demonstrated the following:

• 
  Reduces over 95% of allergens, including allergens related to pet dander and dust mites, from fabrics washed with the detergent
• Extremely low volatile organic compound (VOC) emissions when the detergent is used
• Each ingredient has been reviewed to ensure that there are no added fragrances and that any chemicals with allergenic or sensitizing properties are either absent or at suitably low levels

“We congratulate SWEAT-X Free and Clear detergent on earning the rigorous asthma & allergy friendly® Certification,” shared Kenneth Mendez, CEO and president of AAFA. “The bar for certification is high, but the power of our scientific testing is in service to our asthma and allergy community. Products that are CERTIFIED asthma & allergy friendly® provide consumers with a trusted solution.”

Consumers want to be confident that a laundry detergent can remove allergens like dust mite and pet allergens,” Dr. John McKeon, CEO of ASL, explains. “Laundry detergents can contain irritant or allergenic ingredients that can impact sensitive airways. I am thrilled the allergy aware consumer can now select a detergent that addresses these issues, has passed our rigorous scientific standards, and is CERTIFIED asthma & allergy friendly®.”

Renegade’s SWEAT-X Free and Clear Laundry Detergent has met these standards and is CERTIFIED to reduce allergens and irritants and contribute to a healthier indoor environment.

“Renegade Brands is proud to join the family of products CERTIFIED asthma & allergy friendly® with our SWEAT-X Free and Clear Laundry Detergent,” said Bill Sherman, CEO of Renegade Brands, Inc. “Our mission has always been to develop and produce the highest quality products and SWEAT-X Free and Clear Detergent is no exception. We are honored to be recognized not only for our product’s efficacy but also for its positive impact in creating a healthier home.”

Renegade’s SWEAT-X Free and Clear Laundry Detergent will be celebrated at the ISSA Trade Show 2021 in Las Vegas Nov. 15-18, 2021, where the focus will be on the importance of cleaning products for healthier indoor living solutions.

About the asthma & allergy friendly® Certification Program

The asthma & allergy friendly® Certification Program is a unique, groundbreaking collaboration between the Asthma and Allergy Foundation of America and Allergy Standards Limited. This program helps people make informed purchases for a #healthierhome. The Program tests household products against strict standards. Products passing these tests, earn the CERTIFIED asthma & allergy friendly® mark. Certified products include air cleaners, bedding, cleaning products, flooring, paints, vacuum cleaners, washing machines and more. Visit aafa.org/certified for more information.

About Renegade Brands, Inc.

Renegade Brands Inc., based in Cleveland, Ohio, is owned and operated by a group of athletes who believe in challenging the detergent industry’s status quo by delivering the highest performance sports laundry products on the market. Renegade Brands’ powerful and proprietary nano-scale cleaning system is robustly engineered to eliminate odor, remove stains and restore fabric performance for athletes everywhere.

For more information visit http://www.sweatxsport.com.

For press materials, interview quotes, and high-resolution photography for the Certification Program and more information about our CERTIFIED client partners, please contact Sarajane Sparks, PR/Marketing for the Certification Program.

Share article on social media or email:

“As healthcare demands grow and change, we are investing in innovative products that will allow our customers the flexibility they need to design and manufacture next-generation healthcare solutions,” said DuPont Healthcare EMEA Marketing Manager Michele Vigliotti.

WILMINGTON, Del. (PRWEB)
November 09, 2021

DuPont (NYSE:DD) today announced that it will highlight new DuPont™ Liveo™ Healthcare Solutions product lines at CPhI Worldwide 2021, which will take place Nov. 9 through 11 in Milan, Italy. The new products are being featured in both the DuPont booth and Biesterfeld Spezialchemie booth and include:

• 
  Liveo™ Pharma TPE Tubing – A range of extruded thermoplastic elastomer (TPE) pharma tubing dedicated to fluid transport and single-use bioprocessing applications, produced under similar high-quality and high-purity principles as Liveo™ Silicone Pharma Tubing. On display in Hall 4, Booth 4J71 (DuPont).
• Liveo™ Pharma Bottle Closures – Closures specifically designed to seal threaded glass and plastic bottles and containers used for critical fluid transfer, media and buffer pooling and storage, and sample collection in biopharmaceutical and biotechnology processes. On display in Hall 4, Booth 4J71 (DuPont).
• Liveo™ Topical Film-Formers – Topical excipients to be added to liquid or semi-solid compound formulations to produce a thin, transparent, flexible and substantive film when applied to the skin surface. In medicated products, the excipient also acts as a matrix to stabilize and effectively release the drug to and through the skin. The film-formers are long-lasting, removable, breathable, comfortable, and compatible with APIs and skin penetration enhancers. On display in Hall 9, Booth D60 (Biesterfeld).

“As healthcare demands grow and change, we are investing in innovative products that will allow our customers the flexibility they need to design and manufacture next-generation healthcare solutions,” said DuPont Healthcare EMEA Marketing Manager Michele Vigliotti.

Over the last 70-plus years, DuPont – a trusted partner in the healthcare processing industry – has developed a leadership position within the industry by building upon foundational capabilities that serve the highly regulated biopharmaceutical market and the topical pharmaceutical market.

The release of these new products and the company’s recent investments cement its commitment to serving the healthcare market by offering high-quality, high-performance solutions; application and material science expertise; and strong regulatory support.

Visit the CPhI Worldwide 2021 website at cphi.com/europe for more information about the event.

About DuPont™ Liveo™ Healthcare Solutions

DuPont™ Liveo™ is a globally recognized leader in technology for a broad range of innovations in medical devices, biopharmaceutical processing and pharmaceutical solutions. DuPont high-performance materials help create safer healthcare environments and protect the health of patients and healthcare providers worldwide. We help enable smarter healthcare and positive patient outcomes. More information can be found at liveo.dupont.com.

About DuPont Electronics & Industrial

DuPont Electronics & Industrial is a global supplier of new technologies and performance materials serving the semiconductor, circuit board, display, digital and flexographic printing, healthcare, aerospace, industrial, and transportation industries. From advanced technology centers worldwide, teams of talented research scientists and application experts work closely with customers, providing solutions, products and technical service to enable next-generation technologies.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at http://www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

# # #

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

11/9/21

Images:

Proposed caption: New high-quality, high-purity DuPont™ Liveo™ Pharma TPE Tubing and DuPont™ Liveo™ Pharma Bottle Closures

High resolution: https://www.dupont.com/content/dam/dupont/amer/us/en/liveo/public/images/articles/16699_TPE_tubing_bottle_closure-a.jpg

Low resolution: https://www.dupont.com/content/dam/dupont/amer/us/en/liveo/public/images/articles/16699_TPE_tubing_bottle_closure-b.jpg

Proposed caption:

New DuPont™ Liveo™ silicone film-formers are long-lasting, removable, breathable, comfortable, and compatible with APIs and skin penetration enhancers

High resolution:

https://www.dupont.com/content/dam/dupont/amer/us/en/liveo/public/images/articles/film-former-spray.jpg

Share article on social media or email:

HABRI logo

“As the first project to longitudinally examine the impact of pet ownership on the development of LGBTQ+ young adults, this work addresses an important gap in the field of HAI research.”

WASHINGTON (PRWEB)
November 09, 2021

The Human Animal Bond Research Institute (HABRI) announced today the award of a new research grant to Virginia Commonwealth University (VCU) to examine the relationship between sexual and gender minority (SGM) stressors in young adulthood and human-animal interaction (HAI), investigating how pets may serve as a protective factor for this marginalized population during the transition to adulthood. The lead investigators of the grant are Drs. Rosalie Corona and Shelby McDonald, both in the Department of Psychology.

SGM emerging adults (e.g., lesbian, gay, bisexual, transgender, queer, and other sexual and gender minority identities or “LGBTQ+” ́) are a diverse group of young people facing stigma, victimization, and discrimination at levels that impact their wellbeing. This research project involves a three-wave panel study of 300 SGM emerging adults. Over a 6-month period, researchers aim to identify unique relations between SGM stressors and HAI, exploring how pets are associated with increases in personal hardiness, and whether comfort derived from them buffers the negative impact of victimization on self-esteem. This study will allow researchers to assess these effects over time and identify causal mechanisms that explain the relationship between pets and improved health outcomes, providing further evidence for the role of pets as a social determinant of health.

“This study is the first to longitudinally test whether relationships with pets help this underserved population cope with stress,” said Dr. Shelby McDonald, Co-Principal Investigator. “I’m thrilled to be working with Co-PI Dr. Rosalie Corona, on this project, who brings expertise in reducing risk, health disparities, and improving health behaviors. We expect to find that measures of the human-animal bond, such as attachment to pets and comfort derived from pets, will be positively associated with self-esteem and personal hardiness, and negatively associated with stress and substance use.”

Dr. Corona shared, “Findings from this project have important public health and policy implications for promoting the health of SGM emerging adults and could lay the foundation for health promotion of younger and older SGM individuals.”

“As the first project to longitudinally examine the impact of pet ownership on the development of LGBTQ+ young adults, this work addresses an important gap in the field of HAI research,” said Steven Feldman, president of HABRI. “HABRI is committed to diversity, equity and inclusion and is proud to be funding research to advance this commitment.”

About HABRI

HABRI is a not-for-profit organization that maintains the world’s largest online library of human-animal bond research and information; funds innovative research projects to scientifically document the health benefits of companion animals; and informs the public about human-animal bond research and the beneficial role of companion animals in society. For more information, please visit http://www.habri.org.

###

Share article on social media or email:

By giving all patients better financing options we can help growing healthcare practices care for more patients.

DALLAS (PRWEB)
November 09, 2021

Covered Care, a buy now pay later solution for the healthcare industry, announced today the first 0% APR buy now, pay later pricing in the industry that is available to every patient – no matter their credit score. The financing offer is not a promotional price, but rather a true 0% APR offer with no hidden fees.

“Many of the so-called 0% APR offers are either only available to patients with high credit scores or are merely promotional rates that can trigger large retroactive fees if not paid off on time,” said Ken Rees, CEO of Covered Care. “We believe that every patient deserves fair, transparent pricing without any surprises.”

With the new 0% APR pricing, patients using Covered Care financing will be able to choose between a 0%, 6 month offer and a longer-term offer with a low monthly payment. “According to a recent Gallop poll, one-third of American adults don’t receive or delay the medical care they need due to cost,” said Tim Ranney, Chief Risk Officer of Covered Care. “By giving all patients better financing options we can help growing healthcare practices care for more patients.”

Founded in 2020, Covered Care helps healthcare providers care for patients who otherwise would have been declined for traditional credit. Their proprietary financing platform can underwrite and approve patients at every credit level – from prime to non-prime. This flexibility allows healthcare providers to care for more patients without taking on any risk.

About Covered Care

Covered Care is a buy now, pay later financing solution for growing healthcare practices. Our mission is to help healthcare providers care for more patients, which means we provide the highest approval rates in the industry (up to 100%), affordable terms (as low as 0% APR for all credit tiers), and flexible pricings integration options. For more information, visit CoveredCare.com.

Share article on social media or email:

“The Pancreatic Cancer Early Detection (PRECEDE) Consortium is the largest pancreatic cancer initiative in history. It will set the tone and stage for initiatives to come.”

CHANDLER, Ariz. (PRWEB)
November 09, 2021

The Onco’Zine Brief with Peter Hofland, Ph.D. released a new episode of the program via PRX | Public Radio Exchange in the (United States) and UK Health Radio (United Kingdom and Europe). The program is also available via podcast and streaming media.

In the latest episode of The Onco’Zine Brief, Hofland talks with Diane M. Simeone, MD, Principal Investigator of the Pancreatic Cancer Early Detection (PRECEDE) Consortium and Director of the Pancreatic Cancer Center at NYU Langone Health, and Tom Schoenherr, Chief Executive Officer of Ambry Genetics.

Pancreatic ductal adenocarcinoma (PDAC), a disease with a high degree of malignancy, is a common cause of cancer-related morbidity and mortality. This is primarily due to difficulties in detecting early-stage disease and the aggressive behavior of the disease. And while multiple therapeutic strategies have been developed to treat pancreatic cancer, the outcomes of these approaches have, so far, been disappointing. [1]

According to the American Cancer Society, the disease is one of the deadliest cancers, with a 5-year survival rate of just 10 percent. [2]

“Pancreatic cancer is the cancer everybody hears about but doesn’t want to get. It’s been thought of as being uncommon, but over the years the incidence has been increasing. Unfortunately, the survival rate has remained quite low over the last decade or two,” said Simeone.

Challenges

In contrast to some other cancers, including breast cancer and colorectal cancer (CRC), early diagnoses of pancreatic cancer remains challenging.

“Early detection of colon cancer and breast cancer by the use of colonoscopy and mammography have been game-changers in improving survival in these two types of cancer. We don’t have a version of a colonoscopy for pancreatic cancer. We don’t have mammography like breast cancer does, and the 5-year survival rate for breast cancer is 90%. When you look at significant improvement with cancer survival rates, it’s often early detection that has made the most impact. It really needs to be our targeted focus in pancreatic cancer as well,” explained Simeone.

One of the most significant obstacles in advancing early detection and diagnosis is figuring out who is at elevated risk for pancreatic cancer. Efforts to tackle early detection in pancreatic cancer have been small in scale, disjointed, and inadequately funded. A large scale, collaborative effort will be needed to tackle this. The PRECEDE Consortium was established to develop a more organized and effective approach to tackle early detection at the scale and pace needed to have a meaningful impact on patient survival .

PRECEDE, a highly collaborative international effort comprised of over 39 leading academic medical centers across the globe, is committed to transforming the early detection and prevention of pancreatic cancer, with the aim of increasing the 5-year survival rate from 10 percent to 50 percent within the next 10 years.

“We believe this is the largest pancreatic cancer initiative in history. It will set the tone and stage for initiatives to come. I think this will be a catalyst to ignite a bigger spark for visibility on this issue,” said Tom Schoenherr, Chief Executive Officer for Ambry Genetics.

Building a Team

PRECEDE is made possible thanks to partnerships with REALM IDx and its subsidiaries, Ambry Genetics and Invicro. PRECEDE plans to analyze and standardize data curated through LATTICE™, an integrated diagnostics platform operating in the cloud.

“Some of the most cutting-edge technologies in artificial intelligence, machine learning, and genetics actually happens in the private sector. The key is finding the right partners with the same goals as the Consortium to help amplify our progress. That’s why we are working with our partners to create what we call the LATTICE™ project, a platform that runs operates in the cloud and utilizes a HIPAA-eligible service that helps organizations store, transform, query, and analyze health data. This platform will help researchers and clinicians gain new insights for detecting and preventing pancreatic cancer,” said Simeone

To learn more about the PRECEDE Consortium, visit Precedestudy.org and listen to the latest episode of The Onco’Zine Brief on your preferred listening app or via your network of choice. This episode (PRECEDE: Transforming the Early Detection and Prevention of Pancreatic Cancer) is available across multiple broadcast networks and podcast platforms, including PRX Public Radio Exchange, UK Health Radio, Spotify, Audible, Apple Podcasts, iHeart Radio, Google Podcasts, and many others.

About The Onco’Zine Brief

The Onco’Zine Brief, produced by Sunvalley Communication, the publishers of Onco’Zine and ADC Review | Journal of Antibody-drug Conjugates, is an interview and discussion program presented covering a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world. The Onco’Zine Brief, presented by Peter Hofland, Ph.D., is a sponsor-supported, program for healthcare professionals involved in the management and care of cancer patients as well as cancer patients and their family and friends. In the United States the program is distributed via PRX | Public Radio Exchange. In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). The program is also available via most podcasts and streaming media services, including Audible, iTunes, Spotify, and iHeart Radio. Check local listings for more information. For more information about The Onco’Zine Brief or how to sponsor or support this radio broadcast and podcast download our Media Kit. To become a Sustaining member of the program, visit Patreon. For more information about cancer and cancer treatments, visit our online journal Onco’Zine. To sign up for The Onco’Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

About the PRECEDE Consortium

Founded in 2018, The PRECEDE Consortium’s mission is to increase the survival of patients diagnosed with pancreatic cancer from 10% to 50% in the next 10 years. This highly collaborative international effort includes partnerships with top researchers, industry and academic institutions, survivors, and families. Each partner is dedicated to improving early detection, screening, risk modeling, and prevention of this potentially devastating disease. The largest endeavor of its kind, PRECEDE aims to more accurately define who is at risk, determine at what level, and enroll them in state-of-the-art screening programs. Together, we can help put an end to pancreatic cancer. For for information go to precedestudy.org.

About REALM IDx, Inc.

REALM IDx, Inc. is a healthcare company in the field of Integrated Diagnostics (IDx), an advanced field of clinical science that brings together laboratory medicine, radiology, pathology, and sophisticated artificial intelligence to derive actionable insights that predict, diagnose, and treat disease. Powered by proprietary software platforms, best-in-class genomics technology from Ambry Genetics Corporation, and industry-leading radiology and pathology services from Invicro, LLC, the company collects, analyzes, and reports on multi-modal precision diagnostic data sets. REALM’s network of healthcare providers and pharmaceutical partners is expected to drive clinical access to innovations that may lead to better medical solutions for patient care. To learn more, visit REALMIDx.com.

Clinical trial

Pancreatic Cancer Early Detection Consortium (PRECEDE) – ClinicalTrials.gov Identifier: NCT04970056.

Reference

[1] Gallo M, Adinolfi V, Morviducci L, Acquati S, Tuveri E, Ferrari P, Zatelli MC, Faggiano A, Argentiero A, Natalicchio A, D’Oronzo S, Danesi R, Gori S, Russo A, Montagnani M, Beretta GD, Di Bartolo P, Silvestris N, Giorgino F. Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. ESMO Open. 2021 Jun;6(3):100155. doi: 10.1016/j.esmoop.2021.100155. Epub 2021 May 19. PMID: 34020401; PMCID: PMC8144346.

[2] American Cancer Society. Cancer Facts & Figures 2021. Atlanta, Ga: American Cancer Society; 2021.

[3] National Cancer Institute (NCI) The Surveillance, Epidemiology, and End Results (SEER) Program. seer.cancer.gov/. Last accessed on October 26, 2021.

CRANBURY, N.J. (PRWEB)
November 09, 2021

Forty of the nation’s most promising young oncology professionals will be recognized during the “40 Under 40 in Cancer – Class of 2021” virtual ceremony on Wednesday, December 1, at 6:30 pm ET.

The RSVP link for the virtual awards event is http://www.tlg.site/2021-40U40VC.

Created by The Lynx Group in 2018, “40 Under 40 in Cancer” is an awards initiative to identify and recognize the contributions being made across the field of cancer by rising stars and emerging leaders under the age of 40 years.

Nominations come from across the country and represent the following categories:

• 
  Biopharma, Diagnostics, and Devices
• Clinical and Patient Care Professional
• Government, Regulatory, and Payer
• Patient Advocacy and Policy
• Research, Science, and Technology

Finalists and awardees are selected by a panel of reviewers from across diverse roles in oncology.

More information about “40 Under 40 in Cancer” awards, the nomination process, and the awards ceremony can be found at 40under40incancer.com.

The “40 Under 40 in Cancer” 2021 nominees include the following:

Biopharma, Diagnostics, and Devices:

Laura Leoni | Ipsen

Bryan Conner | Regeneron

Clinical and Patient Care Professional:

Mi (Emma) Zhou, MSW, LCSW | Mount Sinai Health System

Megan Langer, PharmD, BCOP | Allegheny Health Network

Anant Mandawat, MD | Emory University School of Medicine

Danya Garner, MSN, RN, OCN, CCRN-K, NPD-BC | M.D. Anderson Cancer Center

Brette Conliffe, PharmD, BCOP | UofL Health – James Graham Brown Cancer Center

Bob T. Li, MD, PhD, MPH | Memorial Sloan Kettering Cancer Center

Konstantinos Leventakos | Mayo Clinic

Erica Fischer-Cartlidge DNP, CNS, CBCN®, AOCNS®, EBP-C | Memorial Sloan Kettering Cancer Center

Julia Harwood | New York Cancer and Blood Specialists

Erin Price, MSW, LICSW, OSW-C | Smith Center for Healing and the Arts

John Khoury, MD | The Oncology Institute of Hope and Innovation

Jorge J. García, PharmD, MS, MHA, MBA, FACHE | Miami Cancer Institute

Thuy Tran, PharmD, CSP | Specialty Pharmacy Service, Atrium Health

Jacob Hobbs | Avera Cancer Center

Oliver S. Eng, MD, FACS | University of Chicago Medical Center

Duncan Allen | OneOncology

Alicia Marie Gesenhues, PharmD, BCOP | Saint Elizabeth Healthcare

Stephen Matthew Schleicher, MD, MBA | Tennessee Oncology

Jocelyn Michelle Leworthy, MSc, CCLS, RECE | Gilda’s Club Simcoe Muskoka

Marissa Fors, LCSW, OSW-C, C-ASWCM, CCM | CancerCare

Government, Regulatory, and Payer:

Star Jones, CPM | State of Wyoming Health Dept/Wyoming Cancer Plan

Jonathan K. Larsen JD, MPP | Temple University’s Beasley School of Law Center for Public Health Law Research

Patient Advocacy and Policy:

Sidney Misigo Chahonyo | Hope for Cancer Kids

Shonna R. Andrews, BSN, RN | Sarah Cannon

Danielle Starling Pardue, Esq. | Triage Cancer

Rebecca Garland | Florida Cancer Specialists/Rx To Go, LLC

Regan Huneycutt | Colorectal Cancer Alliance

Anne Marie F. Rainey, MSN, RN, CHC | Clearview Cancer Institute

Valronica M. Scales, MEd | University of Maryland

Ashley Dedmon, MPH, CHES | Susan G Komen

Taylor Bell Duck, MPA | Merck

Research, Science, and Technology:

Jai N. Patel, PharmD, BCOP, CPP | Levine Cancer Institute

Elizabeth S. McKenna, PhD | Cancer Discovery, American Association for Cancer Research

Christopher Manz | Dana-Farber Cancer Institute

Julio Macias Pimentel, MSCTI | Wayne State University and Karmanos Cancer Institute

Wesley Wilson, MSc, PhD, MRSWA | Perelman School of Medicine at the University of Pennsylvania, Hospital of U Penn

Eleonora Dondossola, PhD | The University of Texas MD Anderson Cancer Center

Nitin Roper MD, MSc | National Cancer Institute

About The Lynx Group

The Lynx Group (TLG) is a premier medical communications and education company acutely focused on oncology and rare disease states. TLG specializes in market access to and with advanced practice providers, patients, and their caregivers. With more than 100 years of combined senior leadership experience, TLG continually creates award-winning medical education and cultivates strong relationships within proprietary brands serving patients and their caregivers, physicians, payers, nurses, pharmacists, navigators, and practice managers.

TLG has broad and deep experience in crafting custom, award winning solutions for life science and biotech companies. Currently, TLG partners with more than 50 of the top pharma and biotech companies globally. TLG proudly serves as co-founder and association management company of the Academy of Oncology Nurse & Patient Navigators (AONN+) and the Association for Value-Based Cancer Care (AVBCC).

About the Association for Value-Based Cancer Care

The Association for Value-Based Cancer Care (AVBCC) is a 501c (6) education organization dedicated to the exchange of knowledge among all stakeholders in the cancer care ecosystem responsible to ensure optimal care and access is delivered to all patients with cancer. The goal of AVBCC is to inform, educate, and foster exchange of current and future state information between all stakeholders: Oncologists and Hematologists, Nurses, Oncology Nurse Navigators, Pathologists and Geneticists, Pharmacists, Practice Administrators, Practice Managers, Patient Advocacy Organizations, Managed Care Organizations, Insurance Companies, Third-Party Payers, Integrated Health Delivery Systems, Cancer Centers of Excellence, Medical Directors, Pharmacy Directors, Pharmaceutical and Biotech Manufacturers, Personalized Medicine Providers, Researchers, and, of course, cancer patients.

Carol Bustos, (732) 992-1893

cbustos@the-lynx-group.com